Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme
H-Y OuT-J Wu

Abstract

Metformin has been widely used in clinical type 2 diabetes treatment and prevention. The present study was designed to explore the effect on people with a sedentary lifestyle at therapeutic doses. Twenty-two physically-inactive volunteers with normal glucose tolerance were studied. Escalating doses of metformin in low-dose (250 mg), intermediate-dose (500 mg), and high-dose (750 mg) treatment three times per day were administrated into each subject for a three-week treatment period. Fasting plasma glucose, A1C, HOMA-IR for insulin resistance, lipid profile, and plasma beta-endorphin-like immunoreactivity (BER) were measured before treatment and weekly at the end of each dosing period. Metformin significantly reduced fasting plasma glucose and HOMA-IR in healthy humans after receiving this treatment at therapeutic doses including low-dose (5 %, 17 %), intermediate-dose (6 %, 25 %) and high-dose treatment (6 %, 21 %). Plasma BER was also increased from 135.46 +/- 61.73 pg/ml to 137.52 +/- 66.11 pg/ml by low-dosing (p = 0.39), to 139.17 +/- 64.08 pg/ml by intermediate-dosing (p = 0.32), and to 149.59 +/- 63.32 pg/ml by high-dosing (p < 0.05). Also, serum cholesterol decreased significantly using metformin at therapeutic doses incl...Continue Reading

Citations

Jan 5, 2008·Current Diabetes Reports·Peter E H SchwarzJaakko Tuomilehto
Jul 27, 2012·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Raj Kumar YadavSushil Chandra Mahapatra
Jan 7, 2014·Metabolic Syndrome and Related Disorders·Botond Literáti-NagyZoltán Szilvássy
Sep 22, 2012·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Krzysztof LabuzekBogusław Okopień
Apr 17, 2015·European Journal of Drug Metabolism and Pharmacokinetics·Yan-Rong MaXin-An Wu
Feb 6, 2018·Journal of Endocrinological Investigation·V GuarnottaC Giordano
Jun 3, 2016·The American Journal of Clinical Nutrition·Benjamin B AlbertWayne S Cutfield
Jul 16, 2021·Journal of Complementary & Integrative Medicine·Samruddhi KavishwarYogesh A Kulkarni
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.